In its “FDA Roundup: February 4, 2022,” the FDA announced that “on Feb. 2, the FDA determined that beginning on Feb. 7, the agency will resume conducting domestic surveillance inspections across all commodities given the decline in COVID-19 cases across the country.”
The FDA says that it will continue to conduct mission‑critical foreign and domestic inspections. In addition, the Agency noted that it will begin conducting previously planned foreign surveillance inspections where the CDC has determined that the threat of COVID-19 falls within its Level 1 or 2 travel recommendations relative to the pandemic. Where there is still a high risk of COVID-19, the Agency stresses that it will continue to leverage a variety of tools to assess facilities. The full FDA announcement can be found here.
